

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Llinas-Brunet, M. et al

Appln. No.

09/368,670

Filed:

08/05/1999

For:

Hepatitis C Inhibitor Peptides

Atty. Docket No. 13/063-2-C2

Box Sequence

U. S. Patent and Trademark Office

P. O. Box 2327

Arlington, VA 22202

Group Art Unit: 1653

Examiner: D. Luktop-

RECEIVED AUG 0 5 2002

TECH CENTER 1600/2900

SUBMISSION OF DUPLICATE SEQUENCE LISTING DISKETTE

Sir:

In response to the communication dated February 6, 2002, setting a one month period for response, a new computer readable form (CRF) Sequence Listing was submitted on February 12, 2002. A copy of the receipted return post card is enclosed.

Since the Applicant has received no response from the Office for that submission, a duplicate computer readable form (CRF) Sequence Listing is enclosed. Since the original submission was timely filed, we believe no fee for an extension of time is due at this time.

The Commissioner is hereby authorized to charge any other fee which may be required, and to credit any overpayment, to Deposit Account No. 02-2955. Triplicate copies of this paper are enclosed.

Respectfully submitted,

Philip I. Datlow

Attorney for Applicant(s)

Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-4542 Date: July 30, 2002

"EXPRESS MAIL" LABEL NO.: EV 000930173 US DEPOSIT DATE: July 30, 2002


I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO:

BOX SEQUENCE U. S. PATENT AND TRADEMARK OFFICE P. O. BOX 2327 ARLINGTON, VA 22202

Philip I. Datlow

Reg. No. 41,482





13/063-2-62

APPLICANT(S): Llinas-Brunet, M. et al

09/368,670 SERIAL NO.: FILING DATE: 08/05/99 13/063-2-C2 DOCKET NO.:

Hepatitis C Inhibitor Peptides TITLE:

IN CONNECTION WITH THE ABOVE CASE, PLEASE DATE STAMP TO ACKNOWLEDGE RECEIPT OF THE DOCUMENTS LISTED BELOW, AND RETURN TO ADDRESSEE.

Statement Under 37 CFR § 1.821(f)
Sequence Listing (Diskette)

Mailed: February 12, 2002



